CleanTech Lithium PLC, a Chilean lithium brine developer, received a 'speculative buy' rating and a target price of 22p from Fox-Davies Capital, suggesting nearly triple upside from its current 8p share price. This follows two key milestones: a 40-year lithium operating contract with the Chilean government and a positive pre-feasibility study for its Laguna Verde project, showing strong economics with a $959 million net present value and a 21.2% internal rate of return. The project plans to produce 15,000 tonnes of lithium carbonate annually over 25 years using low-cost direct lithium extraction technology. Fox-Davies highlights the upcoming announcement of a strategic partner and a potential dual listing on the ASX as major catalysts, despite risks like high capital needs and unproven technology at scale. The lithium project remains highly undervalued compared to peers, offering significant growth potential.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
